Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AARP Medicare Rx Forecast For 2003: Bill Likely, Funding Level Uncertain

Executive Summary

AARP can be flexible about the specific amount of federal funding dedicated to a Medicare prescription drug benefit, association President William Novelli indicated during a National Press Club appearance Nov. 19

You may also be interested in...



PhRMA Plans PR “Offense” In 2003 To Support Effort To Remove Access Issue

PhRMA's reconstituted public affairs program will devote half of its time and staff in 2003 to telling positive stories about the industry

PhRMA Plans PR “Offense” In 2003 To Support Effort To Remove Access Issue

PhRMA's reconstituted public affairs program will devote half of its time and staff in 2003 to telling positive stories about the industry

Medicare Rx Moves To Campaign Trail; AARP Endorses Stripped Down Bill

The Medicare prescription drug benefit debate is moving from Capitol Hill to the campaign trail after the Senate failed to reach agreement on a bill before the August recess

Latest Headlines
See All
UsernamePublicRestriction

Register

PS040825

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel